LAG-3
Lymphocyte activation gene-3; CD223
Lymphocyte activation gene-3 (LAG-3) is an immune checkpoint protein that belongs to the immunoglobulin superfamily. LAG-3 is mainly expressed on activated T cells, NK cells, B cells and plasmacytoid dendritic cells. LAG-3 has a high affinity for MHC class II molecules and can also bind to FGL1. Binding of LAG-3 to its ligands leads to the inhibition of T cell activation and proliferation, thereby regulating the immune response. In the tumor microenvironment, overexpression of LAG-3 is often observed, which helps tumor cells escape immune surveillance. LAG-3 is considered as an important target for cancer immunotherapy. In addition to its role in tumor immunity, LAG-3 is also involved in the pathogenesis of some autoimmune diseases and infectious diseases[1][2][3].
References:
- [1]. Mariuzza RA, Shahid S, Karade SS. The immune checkpoint receptor LAG3: Structure, function, and target for cancer immunotherapy. J Biol Chem. 2024 May;300(5):107241. [Content Brief]
- [2]. Aggarwal V, et al. LAG-3 as the third checkpoint inhibitor. Nat Immunol. 2023 Sep;24(9):1415-1422. [Content Brief]
- [3]. Ren K, et al. Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials. Front Immunol. 2024 Nov 26;15:1501613. [Content Brief]
All Product Categories
-
LAG-3 Related Products (45)
-
Antibodies (1)
-
Relatlimab
0 ImagesSynonyms: BMS-986016Relatlimab (BMS-986016) is a human monoclonal antibody anti-LAG-3 antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC50 value of 0.67 nM and LAG-3/FGL1 interaction with an IC50 value of 0.019 nM. Relatlimab can be used in research of cancer.
-
Anti-Mouse LAG-3 Antibody (C9B7W)
0 ImagesCat. No.: HY-P99141Purity: 99%Anti-Mouse LAG-3 Antibody (C9B7W) is an anti-mouse LAG-3 IgG1 monoclonal antibody. Anti-Mouse LAG-3 Antibody (C9B7W) can enhance CD4+ T cell function and exert anti-tumor effects without blocking the interaction between LAG-3 and MHCII. Anti-Mouse LAG-3 Antibody (C9B7W) can be used for research on cancer such as head and neck squamous cell carcinoma (HNSCC).
-
IMP-761
0 ImagesCat. No.: HY-P991301
-
RBN013209
0 ImagesRBN013209 is an orally active small molecule inhibitor of CD38 with an IC50 of 0.01 to 0.1 μM for human CD38. RBN013209 prevents the conversion of extracellular NAD+ to ADPR or cADPR in tumor cells and PBMCs. RBN013209 can be used in the study of tumor. In addition, RBN013209 enables CAR-T cells to maintain the naive state and central memory state, and decreases the expression of cell activation markers and exhaustion-related inhibitory receptors.
-
CPI-644
0 ImagesCat. No.: HY-122081CAS No.: 1904647-34-2
-
LAGi-DEL
0 ImagesCat. No.: HY-181685LAGi-DEL is a LAG-3 inhibitor, with Kd values of 97.33 nM and 271 nM in surface plasmon resonance (SPR) assay and microscale thermophoresis (MST) assay, respectively. LAGi-DEL blocks the LAG-3/MHC-II interaction, with an EC50 of 138 nM. LAGi-DEL restores T cell activation, enhances IFN-γ secretion and promotes immune-mediated cytotoxicity. LAGi-DEL can be used in the research of acute myeloid leukemia, lung cancer and melanoma.
-
SHR-1802
0 ImagesCat. No.: HY-P992461SHR-1802 is a humanized anti-LAG-3 monoclonal antibody.SHR-1802 specifically binds to LAG-3 and inhibits its binding to major histocompatibility complex class II (MHC-II), fibrinogen-like protein 1 (FGL1), galectin-3, and liver sinusoidal endothelial cell lectin.SHR-1802 can be used for the research of advanced solid tumors.
-
Favezelimab
0 ImagesCat. No.: HY-P99613CAS No.: 2231068-83-8Synonyms: MK-4280; MavezelimabFavezelimab (MK-4280) is a humanized monoclonal antibody targeting LAG-3. Favezelimab blocks the interaction between LAG-3 and its ligand, MHC class II molecules. Favezelimab is applicable to research on relapsed/refractory classical Hodgkin lymphoma, relapsed/refractory diffuse large B-cell lymphoma, and relapsed/refractory indolent B-cell lymphoma. For the isotype control of Favezelimab, refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
-
Tebotelimab
0 ImagesSynonyms: MGD-013Tebotelimab (MGD-013) is a humanized IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC50s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity.
-
Ieramilimab
0 ImagesSynonyms: LAG525; IMP701; Hu5A8Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules. Ieramilimab restores T-cell and NK-cell-mediated antileukemic immunity by reducing exhaustion and augmenting cytokine output and cytotoxicity. Ieramilimab increases the infiltration of cytotoxic T lymphocytes and reduces baseline densities of regulatory T cells (Tregs) and ADAM10-expressing tumor cells. Ieramilimab can be used for the study of various malignancies including melanoma, RCC, and advanced solid tumors.
-
Encelimab
0 ImagesCat. No.: HY-P99922CAS No.: 2173096-82-5
-
Negalstobart
0 ImagesCat. No.: HY-P990750CAS No.: 2360418-68-2Synonyms: IBI-110
-
Brivestobart
0 ImagesSynonyms: GLS-012
-
Tobemstomig
0 ImagesCat. No.: HY-P990700CAS No.: 2648839-43-2Synonyms: RO-7247669; RG-6139
-
Tuparstobart
0 ImagesCat. No.: HY-P990046CAS No.: 2649466-03-3Synonyms: Incagn-02385
-
Alcestobart
0 ImagesSynonyms: LBL-007
